Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose M Rubio

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Psychiatry|May 8, 2025
Clozapine Monitoring in the Post-REMS World: Some Guidance for CliniciansJonathan M Meyer, Jose M Rubio
The Journal of Clinical Psychiatry|April 28, 2017
Duration and Relevance of Untreated Psychiatric Disorders, 2: Nonpsychotic Psychiatric Disorders and Substance Use DisordersJose M Rubio, Christoph U Correll
Schizophrenia Bulletin Open|October 24, 2022
Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?Jose M Rubio, Mercedes Perez-Rodriguez
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom?Christoph U Correll, Jose M Rubio, John M Kane
Behavioural Brain Research|January 8, 2021
Towards a framework to develop neuroimaging biomarkers of relapse in schizophreniaJose M Rubio, Anil K Malhotra, John M Kane
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 2, 2018
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?Christoph U Correll, Jose M Rubio, John M Kane
CNS Drugs|June 1, 2023
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management OptionsJose M Rubio, Daniel Guinart, John M Kane, et al.
Schizophrenia Bulletin|August 6, 2021
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant DataGeorgios Schoretsanitis, John M Kane, Christoph U Correll, et al.
Schizophrenia Research|April 3, 2012
Examining the course of hallucinatory experiences in children and adolescents: a systematic reviewJose M Rubio, Julio Sanjuán, Ludwing Flórez-Salamanca, et al.
Psychiatric Services (Washington, D.C.)|November 10, 2020
Using Claims Data to Assess Treatment Quality of First-Episode PsychosisChristopher Reist, Elise Valdes, Yingqian Ren, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Psychiatry|May 8, 2025
Clozapine Monitoring in the Post-REMS World: Some Guidance for CliniciansJonathan M Meyer, Jose M Rubio
The Journal of Clinical Psychiatry|April 28, 2017
Duration and Relevance of Untreated Psychiatric Disorders, 2: Nonpsychotic Psychiatric Disorders and Substance Use DisordersJose M Rubio, Christoph U Correll
Schizophrenia Bulletin Open|October 24, 2022
Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?Jose M Rubio, Mercedes Perez-Rodriguez
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom?Christoph U Correll, Jose M Rubio, John M Kane
Behavioural Brain Research|January 8, 2021
Towards a framework to develop neuroimaging biomarkers of relapse in schizophreniaJose M Rubio, Anil K Malhotra, John M Kane
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 2, 2018
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?Christoph U Correll, Jose M Rubio, John M Kane
CNS Drugs|June 1, 2023
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management OptionsJose M Rubio, Daniel Guinart, John M Kane, et al.
Schizophrenia Bulletin|August 6, 2021
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant DataGeorgios Schoretsanitis, John M Kane, Christoph U Correll, et al.
Schizophrenia Research|April 3, 2012
Examining the course of hallucinatory experiences in children and adolescents: a systematic reviewJose M Rubio, Julio Sanjuán, Ludwing Flórez-Salamanca, et al.
Psychiatric Services (Washington, D.C.)|November 10, 2020
Using Claims Data to Assess Treatment Quality of First-Episode PsychosisChristopher Reist, Elise Valdes, Yingqian Ren, et al.
Pageof 8